CVS Health Corporation $CVS Shares Purchased by Artemis Investment Management LLP

Key Points

• Artemis Investment Management increased its CVS Health stake by 65.6% in the third quarter, purchasing 20,000 additional shares for a total of 50,481 shares valued at approximately $4.3 million. Institutional investors and hedge funds collectively own 80.66% of CVS shares.
• Analyst sentiment remains positive: 22 analysts rate CVS as a Buy and one rates it Hold, resulting in a consensus “Moderate Buy” rating and an average price target of $107.24.
• CVS reported quarterly EPS of $2.58, exceeding estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company also declared a quarterly dividend of $0.665 per share, equivalent to a 3.0% annualized yield.

Artemis Investment Management LLP grew its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 65.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,481 shares of the pharmacy operator's stock after acquiring an additional 20,000 shares during the period. Artemis Investment Management LLP's holdings in CVS Health were worth $4,326,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Elevation Wealth Partners LLC raised its holdings in CVS Health by 41.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator's stock valued at $37,000 after acquiring an additional 105 shares during the period. Apella Capital LLC lifted its position in shares of CVS Health by 1.7% during the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator's stock valued at $724,000 after acquiring an additional 117 shares during the period. Wellington Altus USA Inc. grew its stake in CVS Health by 13.3% during the second quarter. Wellington Altus USA Inc. now owns 1,025 shares of the pharmacy operator's stock worth $106,000 after buying an additional 120 shares in the last quarter. CoreCap Advisors LLC increased its stake in CVS Health by 4.2% in the second quarter. CoreCap Advisors LLC now owns 3,481 shares of the pharmacy operator's stock valued at $360,000 after acquiring an additional 139 shares during the last quarter. Finally, AGP Franklin LLC lifted its position in shares of CVS Health by 1.3% during the 1st quarter. AGP Franklin LLC now owns 11,563 shares of the pharmacy operator's stock worth $830,000 after buying an additional 146 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CVS has been the topic of several recent research reports. Wells Fargo & Company raised their price objective on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a report on Monday, July 13th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $111.00 to $118.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of CVS Health in a research note on Thursday, October 1st. Barclays upped their price objective on shares of CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. Finally, BMO Capital Markets set a $112.00 price target on shares of CVS Health in a research report on Wednesday, September 9th. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $107.24.

CVS Health Price Performance

Shares of NYSE CVS opened at $87.91 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market cap of $112.43 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.82 and a beta of 0.60. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The stock has a fifty day moving average of $93.10 and a 200-day moving average of $92.41.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the company earned $1.81 earnings per share. The firm's quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Thursday, October 22nd will be given a $0.6650 dividend. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.0%. CVS Health's dividend payout ratio is currently 70.37%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Aetna’s Medicare Advantage quality ratings provide a potential tailwind. CVS said more than 69% of Aetna Medicare Advantage members will be enrolled in plans rated four stars or higher for 2027. Strong CMS ratings can support member retention, enrollment and bonus payments, while reinforcing Aetna’s recovering margins. Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
• Positive Sentiment: Analysts point to several potential growth drivers. CVS trades at a discount to healthcare peers, while Aetna margins are recovering, pharmacy trends are improving and the Health Services segment is gaining momentum. These factors support the view that the stock may be undervalued if the turnaround continues. CVS Health Trades at a Discount to Industry
• Positive Sentiment: Long-term drug distribution agreements improve supply-chain certainty. CVS extended its pharmaceutical distribution contracts with Cardinal Health and McKesson through 2032, supporting reliable nationwide distribution for its retail pharmacies and other dispensing channels. CVS Extends Drug Distribution Deals to 2032
• Neutral Sentiment: CVS is expanding targeted pharmacy access. The company opened its first pharmacy-focused location in the Boston area, a smaller-format model intended to improve medication, vaccination and pharmacist-service access. The initiative may strengthen community presence but is unlikely to materially affect near-term earnings. CVS Opens Pharmacy-Focused Boston Location
• Neutral Sentiment: Unusual options activity signals increased trading interest, not necessarily a fundamental change. Traders purchased approximately 23,271 CVS call options, about 33% above typical volume.
• Negative Sentiment: 340B reimbursement pressures remain a risk. Despite the improving outlook for Aetna and pharmacy operations, continuing 340B headwinds could limit margins and delay the company’s broader earnings recovery. CVS Health Trades at a Discount to Industry

CVS Health Profile

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company's major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.